Aura Biosciences (AURA) Assets Average (2021 - 2026)

Aura Biosciences has reported Assets Average for 6 years, with the latest figure at $153.6 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 9.11% year-over-year to $153.6 million; the trailing twelve-month figure through Mar 2026 stood at $153.6 million (down 9.11% YoY), and the FY2025 full-year result was $176.0 million, down 19.57% from the prior year.
• Assets Average for Q1 2026 stood at $153.6 million, down from $179.7 million in the prior quarter.
• The five-year high for Assets Average was $245.0 million in Q1 2024, with the low at $139.1 million in Q3 2022.
• Historically, Assets Average has averaged $187.7 million across 5 years, with a median of $186.3 million in 2023.
• Annual changes were most pronounced in 2022 — Assets Average soared 46.4% — and 2025, when it slumped 31.05%.
• Aura Biosciences' Assets Average stood at $183.5 million in 2022, then advanced by 18.46% to $217.4 million in 2023, then fell by 10.81% to $193.9 million in 2024, then decreased by 7.32% to $179.7 million in 2025, then decreased by 14.56% to $153.6 million in 2026.
• The last three Assets Average figures came in at $153.6 million (Q1 2026), $179.7 million (Q4 2025), and $197.2 million (Q3 2025), per Business Quant data.